News & Media
2025 / 03 / 20
Triplebar Appoints Shawn Manchester as Chief Executive Officer
[Emeryville, CA] – Triplebar Bio, Inc, a pioneering biotechnology company focused on developing next generation expression systems to reduce the cost of biologics and food protein production, today announced the appointment of Shawn Manchester as its new Chief Executive Officer, effective immediately.
Manchester has been promoted from his role as Chief Operating Officer. He joined Triplebar in 2021 after spending seven years in technical and strategic product roles at Zymergen, Inc. Prior to Zymergen he held research positions at the Massachusetts Institute of Technology (MIT), where he received his PhD in Chemical Engineering. Shawn is an early pioneer in leveraging high-throughput screening and ML approaches to strain and cell line development, and is excited to lead Triplebar as it develops cutting edge technology in this space.
Manchester takes over the role from outgoing CEO, Maria Cho, who led the company since 2022 in a period where Triplebar developed solutions to remove key bottlenecks in the bioeconomy, using a proprietary screening platform to accelerate food and pharma product discovery. Cho successfully completed the company’s $21m fundraising round in 2024.
Founder and CTO of Triplebar, Jeremy Agresti said, “I thank and appreciate Maria for all she did for Triplebar over the past three years. As we move into the next phase of our journey, Shawn’s combined experience in operations, product development and research makes him well-suited to lead Triplebar into the future.”
“I am both honored and humbled to take on the role of CEO at Triplebar,” said Manchester. “We are deeply committed to reducing the cost of biologic therapeutics, and our combination of ulta-high throughput phenotypic screening with genome language models holds immense promise to revolutionize how we develop cell lines.”
About Triplebar:
Triplebar Bio, Inc. is a US-based biotech company prioritizing the development of a “predictive model for life itself” through generative AI genome language models. By leveraging its ultra-high throughput phenotype measurement capabilities, the company can refine genome language models to predict genome edits that impact key cellular functions. This initiative positions Triplebar to disrupt the global food and medicine industries by generating strains and cell lines that produce proteins and biologics at dramatically reduced cost.